A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Phase 2CompletedNCT00168441

Allergan117 enrolled

Overview

4-month study including a 30-day baseline phase

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

117

Conditions

Postherpetic Neuralgia

Interventions

Botulinum Toxin Type ADRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash. Exclusion Criteria: * Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Outcomes

Primary Outcomes

Pain score

Secondary Outcomes

Various Quality of Life questionnaires

Reduction in area of pain/allodynia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.